Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

140.10 -0.82 (-0.58%)

Delayed Quote Updated: 3:46 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Protagonist Therapeutics Topline Data from Phase 2 IDEAL Study of PN-943 (450 mg BID) Miss Primary Endpoint ↗

April 25, 2022

Protagonist Therapeutics (NASDAQ: PTGX) announced top-line results from the Phase 2 IDEAL clinical study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).

Via Benzinga

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

April 21, 2022

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm

April 20, 2022

From The Schall Law Firm

Via Business Wire

Protagonist Therapeutics Earns $25M Milestone Payment From Janssen Biotech ↗

March 16, 2022

Via Benzinga

Analyst Ratings For Protagonist Therapeutics ↗

October 12, 2021

Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 20, 2022

Gainers

Via Benzinga

EQUITY ALERT: Rosen Law Firm Encourages Protagonist Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – PTGX

April 20, 2022

From The Rosen Law Firm, P.A.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 14, 2022

Gainers

Via Benzinga

Protagonist Therapeutics Dives As Its Drama Continues With A New FDA Concern ↗

April 14, 2022

The FDA could revoke a key designation for one of Protagonist's leading drugs.

Via Investor's Business Daily

51 Biggest Movers From Thursday ↗

April 18, 2022

Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More ↗

April 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

April 14, 2022

The biggest pre-market stock movers for Thursday are ready and waiting so let's see what's moving the market this morning!

Via InvestorPlace

FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Cancer ↗

April 14, 2022

Protagonist Therapeutics Inc (NASDAQ: PTGX)

Via Benzinga

Protagonist Therapeutics's Return On Capital Employed Overview ↗

March 03, 2022

Benzinga Pro data, Protagonist Therapeutics (NASDAQ:PTGX) reported Q4 sales of $8.62 million. Earnings fell to a loss of $36.91 million, resulting in a 9.18% decrease from last...

Via Benzinga

3 Desirable Drug Stocks With Very Promising Pipelines ↗

February 16, 2022

Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.

Via InvestorPlace

Protagonist To Go Ahead With Oral Peptide PN-235, Discontinues Phase 1 Candidate ↗

December 03, 2021

Protagonist Therapeutics Inc (NASDAQ: PTGX) has selected PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on the...

Via Benzinga

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering ↗

December 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases...

Via Benzinga

What 9 Analyst Ratings Have To Say About Protagonist Therapeutics ↗

November 15, 2021

Over the past 3 months, 9 analysts have published their opinion on Protagonist Therapeutics (NASDAQ:

Via Benzinga

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

Why Protagonist Therapeutics Stock Skyrocketed 80.2% Last Month ↗

November 08, 2021

Following huge swings over the last two months, the biotech stock is now up 67% year to date.

Via The Motley Fool

5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Augmented Reality Play WiMi Hologram Joins List ↗

November 01, 2021

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A...

Via Benzinga

5 Short Squeeze Candidates To Watch: Progenity, Digital Brands Top List Again, SPAC AGC Joins Ahead Of Merger ↗

October 25, 2021

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A...

Via Benzinga

The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs ↗

October 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas...

Via Benzinga

The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs ↗

October 18, 2021

Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....

Via Benzinga

What 10 Analyst Ratings Have To Say About Protagonist Therapeutics ↗

October 13, 2021

Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

October 13, 2021

MKM Partners raised the price target on Continental Resources, Inc. (NYSE:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 12, 2021

Gainers NRX Pharmaceuticals (NASDAQ:NRXP...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021 ↗

October 12, 2021

Upgrades For Callaway Golf Co (NYSE:ELY), Compass ...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

October 12, 2021

Evercore ISI Group raised Lear Corporation (NYSE:

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.